CD8A and neoplasm: The goal of DC vaccination is to induce or expand functional and long-lived tumor-specific immunity61 and we previously showed that CD8+ T cells were critical to clinical outcome (PFS and OS) as well as vaccine-encoded antigen-specific T-cell responses40.